KREBS BIOCHEMICALS & INDUSTRIES
|
|
BOM : 524518     NSE : KREBSBIO     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward Pledged Shares : None or < 25% |
Feb 08,2023 |
Price(EOD): ₹ 96.95
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 209.41 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
KREBS BIOCHEMICALS & INDUSTRIES | -2.5% | -12% | -43.6% |
SUN PHARMACEUTICAL INDUSTRIES | 0.5% | -0.1% | 12.5% |
DIVIS LABORATORIES | -14.3% | -19.1% | -36.2% |
CIPLA | 1.4% | -4.4% | 9% |
DR REDDYS LABORATORIES | 2.7% | 3.5% | 2.1% |
TORRENT PHARMACEUTICALS | 1% | -0.4% | 14.4% |
ABBOTT INDIA | 3.8% | -4.4% | 32% |
ZYDUS LIFESCIENCES | 9.6% | 7% | 17.2% |
ALKEM LABORATORIES | 3.4% | 4.1% | -12.8% |
FUNDAMENTAL ANALYSIS OF KREBS BIOCHEMICALS & INDUSTRIES
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF KREBS BIOCHEMICALS & INDUSTRIES
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
-7.19
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs -29.07 Cr
[Latest Qtr - Dec2022 - Standalone Results ] -2.78
P/B Calculated based on Book Value of Rs -75.09 Cr
[Latest Year - Mar2022 - Standalone Results ] 3.49
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Dec2022 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
NA -10% 87% |
SHARE PRICE MOMENTUM OF KREBS BIOCHEMICALS & INDUSTRIES
KREBS BIOCHEMICALS & INDUSTRIES vs SENSEX
DEBT OF KREBS BIOCHEMICALS & INDUSTRIES
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
-1.91 -2.37 -2.03 -2.1 |
- - - - |
[Last Annual Data : Mar2022]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF KREBS BIOCHEMICALS & INDUSTRIES
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2022 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF KREBS BIOCHEMICALS & INDUSTRIES
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-56.59% -57.13% -36.76% -36.76% |
-58.32% 69.84% 57.08% 57.08% |
QtrlyTrend |
-2 | |
Latest Qtr: Dec2022 | ||
Quarterly Result Analysis → |
KREBS BIOCHEMICALS & INDUSTRIES related INDICES
You may also like the below Video Courses
FAQ about KREBS BIOCHEMICALS & INDUSTRIES
Is KREBS BIOCHEMICALS & INDUSTRIES good for long term investment?
As on Feb 08,2023, the Fundamentals of KREBS BIOCHEMICALS & INDUSTRIES look Poor and hence it may not be good for long term investment ! See Financial Performance of KREBS BIOCHEMICALS & INDUSTRIES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is KREBS BIOCHEMICALS & INDUSTRIES UnderValued or OverValued?
As on Feb 08,2023, KREBS BIOCHEMICALS & INDUSTRIES is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of KREBS BIOCHEMICALS & INDUSTRIES ?
As on Feb 08,2023, the Intrinsic Value of KREBS BIOCHEMICALS & INDUSTRIES is Rs. 79.71 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. -302.97
Fair Value [Median EV / Sales Model] : Rs. 107.57
Fair Value [Median Price / Sales Model] : Rs. 51.84
Estimated Median Fair Value of KREBS BIOCHEMICALS & INDUSTRIES : Rs. 79.71
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is KREBS BIOCHEMICALS & INDUSTRIES trading at a Premium or Discount?
As on Feb 08,2023, KREBS BIOCHEMICALS & INDUSTRIES is trading at a Premium of 22% based on the estimates of Median Intrinsic Value!